Global Brucellosis Market

Brucellosis Comprehensive Study by Transmission (Raw Dairy Products, Inhaling Contaminated Air, Infected Blood & Body Fluids, Others), Diagnosis (Serological Tests, Molecular Techniques, Bone Marrow Biopsy, X-rays, Computerized Tomography (CT), Magnetic Resonance Imaging (MRI), Cerebrospinal Fluid Culture, Echocardiography, Others), Species (Brucella Suis, Brucella Abortus, Brucella Melitensis, Brucella Canis, Others), End User (Hospitals & Diagnostic Centers, Academic Institutes, Pharmaceutical & Biotechnology Companies, Others) Players and Region - Global Market Outlook to 2028

Brucellosis Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Brucellosis Market Scope
Brucellosis is a bacterial infection that spreads from animals to people most often via unpasteurized milk, cheese, and other dairy products. The infection can usually be treated successfully with antibiotics. Stringent FDA regulatory guidelines for the approval of treatment related to rare disorders.



The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain competitive advantage through combined collaborations.

Hester Biosciences Limited (India), Biogénesis-Bagó S.A. (Argentina), Biovet (India), Merck Animal Health (MSD Animal Health) (United States), Colorado Serum Company (United States), Indian Immunologicals Limited (India), Veterinary Technologies Corporation (Loudoun), China Animal Husbandry Co., Ltd. (China) and BCG Vaccine Laboratory (India) are some of the key players that are part of study coverage.

Segmentation Overview
The study have segmented the market of Global Brucellosis market and Region with country level break-up.

On the basis of geography, the market of Brucellosis has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Influencing Trend:
Rising Investment Interest of Investors Across Different Regions

Market Growth Drivers:
Growing Cases of Endocarditis, Arthritis, CNS Infection and Epididymo-orchitis and Increased Government Funding for the Innovation of Novel Treatment

Challenges:
Lack of Patient Awareness in Developing Countries

Restraints:
Stringent FDA Regulatory Guidelines for the Approval of Treatment

Opportunities:
Growing Healthcare Industry Worldwide and Increasing Research and Development Activities




Key Target Audience
Brucellosiss Vaccine Suppliers, Brucellosiss Drug Manufacturers, Research and Development (R&D) Companies, Medical Research Laboratories and Academic Medical Institutes and Universities

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Report Objectives / Segmentation Covered

By Transmission
  • Raw Dairy Products
  • Inhaling Contaminated Air
  • Infected Blood & Body Fluids
  • Others

By Diagnosis
  • Serological Tests
  • Molecular Techniques
  • Bone Marrow Biopsy
  • X-rays
  • Computerized Tomography (CT)
  • Magnetic Resonance Imaging (MRI)
  • Cerebrospinal Fluid Culture
  • Echocardiography
  • Others

By Species
  • Brucella Suis
  • Brucella Abortus
  • Brucella Melitensis
  • Brucella Canis
  • Others

By End User
  • Hospitals & Diagnostic Centers
  • Academic Institutes
  • Pharmaceutical & Biotechnology Companies
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Cases of Endocarditis, Arthritis, CNS Infection and Epididymo-orchitis
      • 3.2.2. Increased Government Funding for the Innovation of Novel Treatment
    • 3.3. Market Challenges
      • 3.3.1. Lack of Patient Awareness in Developing Countries
    • 3.4. Market Trends
      • 3.4.1. Rising Investment Interest of Investors Across Different Regions
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Brucellosis, by Transmission, Diagnosis, Species, End User and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Brucellosis (Value)
      • 5.2.1. Global Brucellosis by: Transmission (Value)
        • 5.2.1.1. Raw Dairy Products
        • 5.2.1.2. Inhaling Contaminated Air
        • 5.2.1.3. Infected Blood & Body Fluids
        • 5.2.1.4. Others
      • 5.2.2. Global Brucellosis by: Diagnosis (Value)
        • 5.2.2.1. Serological Tests
        • 5.2.2.2. Molecular Techniques
        • 5.2.2.3. Bone Marrow Biopsy
        • 5.2.2.4. X-rays
        • 5.2.2.5. Computerized Tomography (CT)
        • 5.2.2.6. Magnetic Resonance Imaging (MRI)
        • 5.2.2.7. Cerebrospinal Fluid Culture
        • 5.2.2.8. Echocardiography
        • 5.2.2.9. Others
      • 5.2.3. Global Brucellosis by: Species (Value)
        • 5.2.3.1. Brucella Suis
        • 5.2.3.2. Brucella Abortus
        • 5.2.3.3. Brucella Melitensis
        • 5.2.3.4. Brucella Canis
        • 5.2.3.5. Others
      • 5.2.4. Global Brucellosis by: End User (Value)
        • 5.2.4.1. Hospitals & Diagnostic Centers
        • 5.2.4.2. Academic Institutes
        • 5.2.4.3. Pharmaceutical & Biotechnology Companies
        • 5.2.4.4. Others
      • 5.2.5. Global Brucellosis Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Brucellosis: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Hester Biosciences Limited (India)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Biogénesis-Bagó S.A. (Argentina)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Biovet (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Merck Animal Health (MSD Animal Health) (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Colorado Serum Company (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Indian Immunologicals Limited (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Veterinary Technologies Corporation (Loudoun)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. China Animal Husbandry Co., Ltd. (China)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. BCG Vaccine Laboratory (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Brucellosis Sale, by Transmission, Diagnosis, Species, End User and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Brucellosis (Value)
      • 7.2.1. Global Brucellosis by: Transmission (Value)
        • 7.2.1.1. Raw Dairy Products
        • 7.2.1.2. Inhaling Contaminated Air
        • 7.2.1.3. Infected Blood & Body Fluids
        • 7.2.1.4. Others
      • 7.2.2. Global Brucellosis by: Diagnosis (Value)
        • 7.2.2.1. Serological Tests
        • 7.2.2.2. Molecular Techniques
        • 7.2.2.3. Bone Marrow Biopsy
        • 7.2.2.4. X-rays
        • 7.2.2.5. Computerized Tomography (CT)
        • 7.2.2.6. Magnetic Resonance Imaging (MRI)
        • 7.2.2.7. Cerebrospinal Fluid Culture
        • 7.2.2.8. Echocardiography
        • 7.2.2.9. Others
      • 7.2.3. Global Brucellosis by: Species (Value)
        • 7.2.3.1. Brucella Suis
        • 7.2.3.2. Brucella Abortus
        • 7.2.3.3. Brucella Melitensis
        • 7.2.3.4. Brucella Canis
        • 7.2.3.5. Others
      • 7.2.4. Global Brucellosis by: End User (Value)
        • 7.2.4.1. Hospitals & Diagnostic Centers
        • 7.2.4.2. Academic Institutes
        • 7.2.4.3. Pharmaceutical & Biotechnology Companies
        • 7.2.4.4. Others
      • 7.2.5. Global Brucellosis Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Brucellosis: by Transmission(USD Million)
  • Table 2. Brucellosis Raw Dairy Products , by Region USD Million (2017-2022)
  • Table 3. Brucellosis Inhaling Contaminated Air , by Region USD Million (2017-2022)
  • Table 4. Brucellosis Infected Blood & Body Fluids , by Region USD Million (2017-2022)
  • Table 5. Brucellosis Others , by Region USD Million (2017-2022)
  • Table 6. Brucellosis: by Diagnosis(USD Million)
  • Table 7. Brucellosis Serological Tests , by Region USD Million (2017-2022)
  • Table 8. Brucellosis Molecular Techniques , by Region USD Million (2017-2022)
  • Table 9. Brucellosis Bone Marrow Biopsy , by Region USD Million (2017-2022)
  • Table 10. Brucellosis X-rays , by Region USD Million (2017-2022)
  • Table 11. Brucellosis Computerized Tomography (CT) , by Region USD Million (2017-2022)
  • Table 12. Brucellosis Magnetic Resonance Imaging (MRI) , by Region USD Million (2017-2022)
  • Table 13. Brucellosis Cerebrospinal Fluid Culture , by Region USD Million (2017-2022)
  • Table 14. Brucellosis Echocardiography , by Region USD Million (2017-2022)
  • Table 15. Brucellosis Others , by Region USD Million (2017-2022)
  • Table 16. Brucellosis: by Species(USD Million)
  • Table 17. Brucellosis Brucella Suis , by Region USD Million (2017-2022)
  • Table 18. Brucellosis Brucella Abortus , by Region USD Million (2017-2022)
  • Table 19. Brucellosis Brucella Melitensis , by Region USD Million (2017-2022)
  • Table 20. Brucellosis Brucella Canis , by Region USD Million (2017-2022)
  • Table 21. Brucellosis Others , by Region USD Million (2017-2022)
  • Table 22. Brucellosis: by End User(USD Million)
  • Table 23. Brucellosis Hospitals & Diagnostic Centers , by Region USD Million (2017-2022)
  • Table 24. Brucellosis Academic Institutes , by Region USD Million (2017-2022)
  • Table 25. Brucellosis Pharmaceutical & Biotechnology Companies , by Region USD Million (2017-2022)
  • Table 26. Brucellosis Others , by Region USD Million (2017-2022)
  • Table 27. South America Brucellosis, by Country USD Million (2017-2022)
  • Table 28. South America Brucellosis, by Transmission USD Million (2017-2022)
  • Table 29. South America Brucellosis, by Diagnosis USD Million (2017-2022)
  • Table 30. South America Brucellosis, by Species USD Million (2017-2022)
  • Table 31. South America Brucellosis, by End User USD Million (2017-2022)
  • Table 32. Brazil Brucellosis, by Transmission USD Million (2017-2022)
  • Table 33. Brazil Brucellosis, by Diagnosis USD Million (2017-2022)
  • Table 34. Brazil Brucellosis, by Species USD Million (2017-2022)
  • Table 35. Brazil Brucellosis, by End User USD Million (2017-2022)
  • Table 36. Argentina Brucellosis, by Transmission USD Million (2017-2022)
  • Table 37. Argentina Brucellosis, by Diagnosis USD Million (2017-2022)
  • Table 38. Argentina Brucellosis, by Species USD Million (2017-2022)
  • Table 39. Argentina Brucellosis, by End User USD Million (2017-2022)
  • Table 40. Rest of South America Brucellosis, by Transmission USD Million (2017-2022)
  • Table 41. Rest of South America Brucellosis, by Diagnosis USD Million (2017-2022)
  • Table 42. Rest of South America Brucellosis, by Species USD Million (2017-2022)
  • Table 43. Rest of South America Brucellosis, by End User USD Million (2017-2022)
  • Table 44. Asia Pacific Brucellosis, by Country USD Million (2017-2022)
  • Table 45. Asia Pacific Brucellosis, by Transmission USD Million (2017-2022)
  • Table 46. Asia Pacific Brucellosis, by Diagnosis USD Million (2017-2022)
  • Table 47. Asia Pacific Brucellosis, by Species USD Million (2017-2022)
  • Table 48. Asia Pacific Brucellosis, by End User USD Million (2017-2022)
  • Table 49. China Brucellosis, by Transmission USD Million (2017-2022)
  • Table 50. China Brucellosis, by Diagnosis USD Million (2017-2022)
  • Table 51. China Brucellosis, by Species USD Million (2017-2022)
  • Table 52. China Brucellosis, by End User USD Million (2017-2022)
  • Table 53. Japan Brucellosis, by Transmission USD Million (2017-2022)
  • Table 54. Japan Brucellosis, by Diagnosis USD Million (2017-2022)
  • Table 55. Japan Brucellosis, by Species USD Million (2017-2022)
  • Table 56. Japan Brucellosis, by End User USD Million (2017-2022)
  • Table 57. India Brucellosis, by Transmission USD Million (2017-2022)
  • Table 58. India Brucellosis, by Diagnosis USD Million (2017-2022)
  • Table 59. India Brucellosis, by Species USD Million (2017-2022)
  • Table 60. India Brucellosis, by End User USD Million (2017-2022)
  • Table 61. South Korea Brucellosis, by Transmission USD Million (2017-2022)
  • Table 62. South Korea Brucellosis, by Diagnosis USD Million (2017-2022)
  • Table 63. South Korea Brucellosis, by Species USD Million (2017-2022)
  • Table 64. South Korea Brucellosis, by End User USD Million (2017-2022)
  • Table 65. Taiwan Brucellosis, by Transmission USD Million (2017-2022)
  • Table 66. Taiwan Brucellosis, by Diagnosis USD Million (2017-2022)
  • Table 67. Taiwan Brucellosis, by Species USD Million (2017-2022)
  • Table 68. Taiwan Brucellosis, by End User USD Million (2017-2022)
  • Table 69. Australia Brucellosis, by Transmission USD Million (2017-2022)
  • Table 70. Australia Brucellosis, by Diagnosis USD Million (2017-2022)
  • Table 71. Australia Brucellosis, by Species USD Million (2017-2022)
  • Table 72. Australia Brucellosis, by End User USD Million (2017-2022)
  • Table 73. Rest of Asia-Pacific Brucellosis, by Transmission USD Million (2017-2022)
  • Table 74. Rest of Asia-Pacific Brucellosis, by Diagnosis USD Million (2017-2022)
  • Table 75. Rest of Asia-Pacific Brucellosis, by Species USD Million (2017-2022)
  • Table 76. Rest of Asia-Pacific Brucellosis, by End User USD Million (2017-2022)
  • Table 77. Europe Brucellosis, by Country USD Million (2017-2022)
  • Table 78. Europe Brucellosis, by Transmission USD Million (2017-2022)
  • Table 79. Europe Brucellosis, by Diagnosis USD Million (2017-2022)
  • Table 80. Europe Brucellosis, by Species USD Million (2017-2022)
  • Table 81. Europe Brucellosis, by End User USD Million (2017-2022)
  • Table 82. Germany Brucellosis, by Transmission USD Million (2017-2022)
  • Table 83. Germany Brucellosis, by Diagnosis USD Million (2017-2022)
  • Table 84. Germany Brucellosis, by Species USD Million (2017-2022)
  • Table 85. Germany Brucellosis, by End User USD Million (2017-2022)
  • Table 86. France Brucellosis, by Transmission USD Million (2017-2022)
  • Table 87. France Brucellosis, by Diagnosis USD Million (2017-2022)
  • Table 88. France Brucellosis, by Species USD Million (2017-2022)
  • Table 89. France Brucellosis, by End User USD Million (2017-2022)
  • Table 90. Italy Brucellosis, by Transmission USD Million (2017-2022)
  • Table 91. Italy Brucellosis, by Diagnosis USD Million (2017-2022)
  • Table 92. Italy Brucellosis, by Species USD Million (2017-2022)
  • Table 93. Italy Brucellosis, by End User USD Million (2017-2022)
  • Table 94. United Kingdom Brucellosis, by Transmission USD Million (2017-2022)
  • Table 95. United Kingdom Brucellosis, by Diagnosis USD Million (2017-2022)
  • Table 96. United Kingdom Brucellosis, by Species USD Million (2017-2022)
  • Table 97. United Kingdom Brucellosis, by End User USD Million (2017-2022)
  • Table 98. Netherlands Brucellosis, by Transmission USD Million (2017-2022)
  • Table 99. Netherlands Brucellosis, by Diagnosis USD Million (2017-2022)
  • Table 100. Netherlands Brucellosis, by Species USD Million (2017-2022)
  • Table 101. Netherlands Brucellosis, by End User USD Million (2017-2022)
  • Table 102. Rest of Europe Brucellosis, by Transmission USD Million (2017-2022)
  • Table 103. Rest of Europe Brucellosis, by Diagnosis USD Million (2017-2022)
  • Table 104. Rest of Europe Brucellosis, by Species USD Million (2017-2022)
  • Table 105. Rest of Europe Brucellosis, by End User USD Million (2017-2022)
  • Table 106. MEA Brucellosis, by Country USD Million (2017-2022)
  • Table 107. MEA Brucellosis, by Transmission USD Million (2017-2022)
  • Table 108. MEA Brucellosis, by Diagnosis USD Million (2017-2022)
  • Table 109. MEA Brucellosis, by Species USD Million (2017-2022)
  • Table 110. MEA Brucellosis, by End User USD Million (2017-2022)
  • Table 111. Middle East Brucellosis, by Transmission USD Million (2017-2022)
  • Table 112. Middle East Brucellosis, by Diagnosis USD Million (2017-2022)
  • Table 113. Middle East Brucellosis, by Species USD Million (2017-2022)
  • Table 114. Middle East Brucellosis, by End User USD Million (2017-2022)
  • Table 115. Africa Brucellosis, by Transmission USD Million (2017-2022)
  • Table 116. Africa Brucellosis, by Diagnosis USD Million (2017-2022)
  • Table 117. Africa Brucellosis, by Species USD Million (2017-2022)
  • Table 118. Africa Brucellosis, by End User USD Million (2017-2022)
  • Table 119. North America Brucellosis, by Country USD Million (2017-2022)
  • Table 120. North America Brucellosis, by Transmission USD Million (2017-2022)
  • Table 121. North America Brucellosis, by Diagnosis USD Million (2017-2022)
  • Table 122. North America Brucellosis, by Species USD Million (2017-2022)
  • Table 123. North America Brucellosis, by End User USD Million (2017-2022)
  • Table 124. United States Brucellosis, by Transmission USD Million (2017-2022)
  • Table 125. United States Brucellosis, by Diagnosis USD Million (2017-2022)
  • Table 126. United States Brucellosis, by Species USD Million (2017-2022)
  • Table 127. United States Brucellosis, by End User USD Million (2017-2022)
  • Table 128. Canada Brucellosis, by Transmission USD Million (2017-2022)
  • Table 129. Canada Brucellosis, by Diagnosis USD Million (2017-2022)
  • Table 130. Canada Brucellosis, by Species USD Million (2017-2022)
  • Table 131. Canada Brucellosis, by End User USD Million (2017-2022)
  • Table 132. Mexico Brucellosis, by Transmission USD Million (2017-2022)
  • Table 133. Mexico Brucellosis, by Diagnosis USD Million (2017-2022)
  • Table 134. Mexico Brucellosis, by Species USD Million (2017-2022)
  • Table 135. Mexico Brucellosis, by End User USD Million (2017-2022)
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Company Basic Information, Sales Area and Its Competitors
  • Table 144. Company Basic Information, Sales Area and Its Competitors
  • Table 145. Brucellosis: by Transmission(USD Million)
  • Table 146. Brucellosis Raw Dairy Products , by Region USD Million (2023-2028)
  • Table 147. Brucellosis Inhaling Contaminated Air , by Region USD Million (2023-2028)
  • Table 148. Brucellosis Infected Blood & Body Fluids , by Region USD Million (2023-2028)
  • Table 149. Brucellosis Others , by Region USD Million (2023-2028)
  • Table 150. Brucellosis: by Diagnosis(USD Million)
  • Table 151. Brucellosis Serological Tests , by Region USD Million (2023-2028)
  • Table 152. Brucellosis Molecular Techniques , by Region USD Million (2023-2028)
  • Table 153. Brucellosis Bone Marrow Biopsy , by Region USD Million (2023-2028)
  • Table 154. Brucellosis X-rays , by Region USD Million (2023-2028)
  • Table 155. Brucellosis Computerized Tomography (CT) , by Region USD Million (2023-2028)
  • Table 156. Brucellosis Magnetic Resonance Imaging (MRI) , by Region USD Million (2023-2028)
  • Table 157. Brucellosis Cerebrospinal Fluid Culture , by Region USD Million (2023-2028)
  • Table 158. Brucellosis Echocardiography , by Region USD Million (2023-2028)
  • Table 159. Brucellosis Others , by Region USD Million (2023-2028)
  • Table 160. Brucellosis: by Species(USD Million)
  • Table 161. Brucellosis Brucella Suis , by Region USD Million (2023-2028)
  • Table 162. Brucellosis Brucella Abortus , by Region USD Million (2023-2028)
  • Table 163. Brucellosis Brucella Melitensis , by Region USD Million (2023-2028)
  • Table 164. Brucellosis Brucella Canis , by Region USD Million (2023-2028)
  • Table 165. Brucellosis Others , by Region USD Million (2023-2028)
  • Table 166. Brucellosis: by End User(USD Million)
  • Table 167. Brucellosis Hospitals & Diagnostic Centers , by Region USD Million (2023-2028)
  • Table 168. Brucellosis Academic Institutes , by Region USD Million (2023-2028)
  • Table 169. Brucellosis Pharmaceutical & Biotechnology Companies , by Region USD Million (2023-2028)
  • Table 170. Brucellosis Others , by Region USD Million (2023-2028)
  • Table 171. South America Brucellosis, by Country USD Million (2023-2028)
  • Table 172. South America Brucellosis, by Transmission USD Million (2023-2028)
  • Table 173. South America Brucellosis, by Diagnosis USD Million (2023-2028)
  • Table 174. South America Brucellosis, by Species USD Million (2023-2028)
  • Table 175. South America Brucellosis, by End User USD Million (2023-2028)
  • Table 176. Brazil Brucellosis, by Transmission USD Million (2023-2028)
  • Table 177. Brazil Brucellosis, by Diagnosis USD Million (2023-2028)
  • Table 178. Brazil Brucellosis, by Species USD Million (2023-2028)
  • Table 179. Brazil Brucellosis, by End User USD Million (2023-2028)
  • Table 180. Argentina Brucellosis, by Transmission USD Million (2023-2028)
  • Table 181. Argentina Brucellosis, by Diagnosis USD Million (2023-2028)
  • Table 182. Argentina Brucellosis, by Species USD Million (2023-2028)
  • Table 183. Argentina Brucellosis, by End User USD Million (2023-2028)
  • Table 184. Rest of South America Brucellosis, by Transmission USD Million (2023-2028)
  • Table 185. Rest of South America Brucellosis, by Diagnosis USD Million (2023-2028)
  • Table 186. Rest of South America Brucellosis, by Species USD Million (2023-2028)
  • Table 187. Rest of South America Brucellosis, by End User USD Million (2023-2028)
  • Table 188. Asia Pacific Brucellosis, by Country USD Million (2023-2028)
  • Table 189. Asia Pacific Brucellosis, by Transmission USD Million (2023-2028)
  • Table 190. Asia Pacific Brucellosis, by Diagnosis USD Million (2023-2028)
  • Table 191. Asia Pacific Brucellosis, by Species USD Million (2023-2028)
  • Table 192. Asia Pacific Brucellosis, by End User USD Million (2023-2028)
  • Table 193. China Brucellosis, by Transmission USD Million (2023-2028)
  • Table 194. China Brucellosis, by Diagnosis USD Million (2023-2028)
  • Table 195. China Brucellosis, by Species USD Million (2023-2028)
  • Table 196. China Brucellosis, by End User USD Million (2023-2028)
  • Table 197. Japan Brucellosis, by Transmission USD Million (2023-2028)
  • Table 198. Japan Brucellosis, by Diagnosis USD Million (2023-2028)
  • Table 199. Japan Brucellosis, by Species USD Million (2023-2028)
  • Table 200. Japan Brucellosis, by End User USD Million (2023-2028)
  • Table 201. India Brucellosis, by Transmission USD Million (2023-2028)
  • Table 202. India Brucellosis, by Diagnosis USD Million (2023-2028)
  • Table 203. India Brucellosis, by Species USD Million (2023-2028)
  • Table 204. India Brucellosis, by End User USD Million (2023-2028)
  • Table 205. South Korea Brucellosis, by Transmission USD Million (2023-2028)
  • Table 206. South Korea Brucellosis, by Diagnosis USD Million (2023-2028)
  • Table 207. South Korea Brucellosis, by Species USD Million (2023-2028)
  • Table 208. South Korea Brucellosis, by End User USD Million (2023-2028)
  • Table 209. Taiwan Brucellosis, by Transmission USD Million (2023-2028)
  • Table 210. Taiwan Brucellosis, by Diagnosis USD Million (2023-2028)
  • Table 211. Taiwan Brucellosis, by Species USD Million (2023-2028)
  • Table 212. Taiwan Brucellosis, by End User USD Million (2023-2028)
  • Table 213. Australia Brucellosis, by Transmission USD Million (2023-2028)
  • Table 214. Australia Brucellosis, by Diagnosis USD Million (2023-2028)
  • Table 215. Australia Brucellosis, by Species USD Million (2023-2028)
  • Table 216. Australia Brucellosis, by End User USD Million (2023-2028)
  • Table 217. Rest of Asia-Pacific Brucellosis, by Transmission USD Million (2023-2028)
  • Table 218. Rest of Asia-Pacific Brucellosis, by Diagnosis USD Million (2023-2028)
  • Table 219. Rest of Asia-Pacific Brucellosis, by Species USD Million (2023-2028)
  • Table 220. Rest of Asia-Pacific Brucellosis, by End User USD Million (2023-2028)
  • Table 221. Europe Brucellosis, by Country USD Million (2023-2028)
  • Table 222. Europe Brucellosis, by Transmission USD Million (2023-2028)
  • Table 223. Europe Brucellosis, by Diagnosis USD Million (2023-2028)
  • Table 224. Europe Brucellosis, by Species USD Million (2023-2028)
  • Table 225. Europe Brucellosis, by End User USD Million (2023-2028)
  • Table 226. Germany Brucellosis, by Transmission USD Million (2023-2028)
  • Table 227. Germany Brucellosis, by Diagnosis USD Million (2023-2028)
  • Table 228. Germany Brucellosis, by Species USD Million (2023-2028)
  • Table 229. Germany Brucellosis, by End User USD Million (2023-2028)
  • Table 230. France Brucellosis, by Transmission USD Million (2023-2028)
  • Table 231. France Brucellosis, by Diagnosis USD Million (2023-2028)
  • Table 232. France Brucellosis, by Species USD Million (2023-2028)
  • Table 233. France Brucellosis, by End User USD Million (2023-2028)
  • Table 234. Italy Brucellosis, by Transmission USD Million (2023-2028)
  • Table 235. Italy Brucellosis, by Diagnosis USD Million (2023-2028)
  • Table 236. Italy Brucellosis, by Species USD Million (2023-2028)
  • Table 237. Italy Brucellosis, by End User USD Million (2023-2028)
  • Table 238. United Kingdom Brucellosis, by Transmission USD Million (2023-2028)
  • Table 239. United Kingdom Brucellosis, by Diagnosis USD Million (2023-2028)
  • Table 240. United Kingdom Brucellosis, by Species USD Million (2023-2028)
  • Table 241. United Kingdom Brucellosis, by End User USD Million (2023-2028)
  • Table 242. Netherlands Brucellosis, by Transmission USD Million (2023-2028)
  • Table 243. Netherlands Brucellosis, by Diagnosis USD Million (2023-2028)
  • Table 244. Netherlands Brucellosis, by Species USD Million (2023-2028)
  • Table 245. Netherlands Brucellosis, by End User USD Million (2023-2028)
  • Table 246. Rest of Europe Brucellosis, by Transmission USD Million (2023-2028)
  • Table 247. Rest of Europe Brucellosis, by Diagnosis USD Million (2023-2028)
  • Table 248. Rest of Europe Brucellosis, by Species USD Million (2023-2028)
  • Table 249. Rest of Europe Brucellosis, by End User USD Million (2023-2028)
  • Table 250. MEA Brucellosis, by Country USD Million (2023-2028)
  • Table 251. MEA Brucellosis, by Transmission USD Million (2023-2028)
  • Table 252. MEA Brucellosis, by Diagnosis USD Million (2023-2028)
  • Table 253. MEA Brucellosis, by Species USD Million (2023-2028)
  • Table 254. MEA Brucellosis, by End User USD Million (2023-2028)
  • Table 255. Middle East Brucellosis, by Transmission USD Million (2023-2028)
  • Table 256. Middle East Brucellosis, by Diagnosis USD Million (2023-2028)
  • Table 257. Middle East Brucellosis, by Species USD Million (2023-2028)
  • Table 258. Middle East Brucellosis, by End User USD Million (2023-2028)
  • Table 259. Africa Brucellosis, by Transmission USD Million (2023-2028)
  • Table 260. Africa Brucellosis, by Diagnosis USD Million (2023-2028)
  • Table 261. Africa Brucellosis, by Species USD Million (2023-2028)
  • Table 262. Africa Brucellosis, by End User USD Million (2023-2028)
  • Table 263. North America Brucellosis, by Country USD Million (2023-2028)
  • Table 264. North America Brucellosis, by Transmission USD Million (2023-2028)
  • Table 265. North America Brucellosis, by Diagnosis USD Million (2023-2028)
  • Table 266. North America Brucellosis, by Species USD Million (2023-2028)
  • Table 267. North America Brucellosis, by End User USD Million (2023-2028)
  • Table 268. United States Brucellosis, by Transmission USD Million (2023-2028)
  • Table 269. United States Brucellosis, by Diagnosis USD Million (2023-2028)
  • Table 270. United States Brucellosis, by Species USD Million (2023-2028)
  • Table 271. United States Brucellosis, by End User USD Million (2023-2028)
  • Table 272. Canada Brucellosis, by Transmission USD Million (2023-2028)
  • Table 273. Canada Brucellosis, by Diagnosis USD Million (2023-2028)
  • Table 274. Canada Brucellosis, by Species USD Million (2023-2028)
  • Table 275. Canada Brucellosis, by End User USD Million (2023-2028)
  • Table 276. Mexico Brucellosis, by Transmission USD Million (2023-2028)
  • Table 277. Mexico Brucellosis, by Diagnosis USD Million (2023-2028)
  • Table 278. Mexico Brucellosis, by Species USD Million (2023-2028)
  • Table 279. Mexico Brucellosis, by End User USD Million (2023-2028)
  • Table 280. Research Programs/Design for This Report
  • Table 281. Key Data Information from Secondary Sources
  • Table 282. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Brucellosis: by Transmission USD Million (2017-2022)
  • Figure 5. Global Brucellosis: by Diagnosis USD Million (2017-2022)
  • Figure 6. Global Brucellosis: by Species USD Million (2017-2022)
  • Figure 7. Global Brucellosis: by End User USD Million (2017-2022)
  • Figure 8. South America Brucellosis Share (%), by Country
  • Figure 9. Asia Pacific Brucellosis Share (%), by Country
  • Figure 10. Europe Brucellosis Share (%), by Country
  • Figure 11. MEA Brucellosis Share (%), by Country
  • Figure 12. North America Brucellosis Share (%), by Country
  • Figure 13. Global Brucellosis share by Players 2022 (%)
  • Figure 14. Global Brucellosis share by Players (Top 3) 2022(%)
  • Figure 15. Global Brucellosis share by Players (Top 5) 2022(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Hester Biosciences Limited (India) Revenue, Net Income and Gross profit
  • Figure 18. Hester Biosciences Limited (India) Revenue: by Geography 2022
  • Figure 19. Biogénesis-Bagó S.A. (Argentina) Revenue, Net Income and Gross profit
  • Figure 20. Biogénesis-Bagó S.A. (Argentina) Revenue: by Geography 2022
  • Figure 21. Biovet (India) Revenue, Net Income and Gross profit
  • Figure 22. Biovet (India) Revenue: by Geography 2022
  • Figure 23. Merck Animal Health (MSD Animal Health) (United States) Revenue, Net Income and Gross profit
  • Figure 24. Merck Animal Health (MSD Animal Health) (United States) Revenue: by Geography 2022
  • Figure 25. Colorado Serum Company (United States) Revenue, Net Income and Gross profit
  • Figure 26. Colorado Serum Company (United States) Revenue: by Geography 2022
  • Figure 27. Indian Immunologicals Limited (India) Revenue, Net Income and Gross profit
  • Figure 28. Indian Immunologicals Limited (India) Revenue: by Geography 2022
  • Figure 29. Veterinary Technologies Corporation (Loudoun) Revenue, Net Income and Gross profit
  • Figure 30. Veterinary Technologies Corporation (Loudoun) Revenue: by Geography 2022
  • Figure 31. China Animal Husbandry Co., Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 32. China Animal Husbandry Co., Ltd. (China) Revenue: by Geography 2022
  • Figure 33. BCG Vaccine Laboratory (India) Revenue, Net Income and Gross profit
  • Figure 34. BCG Vaccine Laboratory (India) Revenue: by Geography 2022
  • Figure 35. Global Brucellosis: by Transmission USD Million (2023-2028)
  • Figure 36. Global Brucellosis: by Diagnosis USD Million (2023-2028)
  • Figure 37. Global Brucellosis: by Species USD Million (2023-2028)
  • Figure 38. Global Brucellosis: by End User USD Million (2023-2028)
  • Figure 39. South America Brucellosis Share (%), by Country
  • Figure 40. Asia Pacific Brucellosis Share (%), by Country
  • Figure 41. Europe Brucellosis Share (%), by Country
  • Figure 42. MEA Brucellosis Share (%), by Country
  • Figure 43. North America Brucellosis Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Hester Biosciences Limited (India)
  • Biogénesis-Bagó S.A. (Argentina)
  • Biovet (India)
  • Merck Animal Health (MSD Animal Health) (United States)
  • Colorado Serum Company (United States)
  • Indian Immunologicals Limited (India)
  • Veterinary Technologies Corporation (Loudoun)
  • China Animal Husbandry Co., Ltd. (China)
  • BCG Vaccine Laboratory (India)
Select User Access Type

Key Highlights of Report


May 2023 225 Pages 60 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Brucellosis Market Quantitative research analysis
Global Brucellosis Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Brucellosis study can be customized to meet your requirements. The market size breakdown by type, by end-use application.
The Brucellosis Market is gaining popularity and expected to see strong valuation by 2028 .
According to AMA, the Global Brucellosis market is expected to see growth rate of xx%.
The Brucellosis market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete of companies available in our research coverage.

Know More About Global Brucellosis Market Report?

Have a Query? Click Here

Other Related Reports

Carrion's Disease Comprehensive Study by Antibiotics (Chloramphenicol, Azithromycin, Erythromycin, Ciprofloxacin, Rifampin, Macrolides), Stages (Acute Phase, Chronic Phase), End User (Hospitals, Clin...
$ 3500
Campylobacteriosis Comprehensive Study by Application (Hospitals, Clinics, Private Laboratories, Independent Physician Chambers, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Onl...
$ 3750
Bronchiolitis Comprehensive Study by Type (Viral Bronchiolitis, Bronchiolitis Obliterans), Treatment (Flu Shot, Corticosteroids, Intravenous Fluid Treatment, Others), End-users (Hospitals, Clinics, O...
$ 3650
Bacterial Meningitis Comprehensive Study by Type (Pneumococcal meningitis, Meningococcal meningitis, Listeria monocytogenes meningitis, Neonatal meningitis, Hemophilus (Hib) meningitis), Treatment (A...
$ 3750
Burkholderia Cepacia Infection Comprehensive Study by Application (Kids, Adults), Drug Type (Trimethoprim, Sulfamethoxazole, Trimethoprim and sulfamethoxazole, Meropenem, Minocycline, Cefepime, Tigec...
$ 3650
Transitional Cell Carcinoma Comprehensive Study by Application (Hospitals, Cancer Palliative care clinics, Diagnostic centers, Pharmacies), Drug (Levatinib, Atezolizumab, Nivelumab, Enzalutamide, Abi...
$ 3750